QUANTITATION OF ESTROGEN RECEPTOR CONCENTRATION IN CELLS

细胞中雌激素受体浓度的定量

• 批准号: 3491511
• 负责人: JAMES W BACUS
• 金额: $ 4.86万
• 依托单位: CELL ANALYSIS SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-06-15 至 1986-12-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3491511
• 关键词: artificial intelligence; breast neoplasm /cancer diagnosis; cell population study; clinical biomedical equipment; computer data analysis; image processing; immunochemistry; microscopy; monoclonal antibody; neoplastic cell; prognosis; single cell analysis; stainings

The objective of this project is to develop quantitative estrogen receptor concentration measurements using high resolution digital image microscopy techniques. These techniques will enable direct mesurements of receptor concentration on a cell by cell basis. This is an improvement over the current biochemical assays which only give an average value for receptor concentration. The quantitative assay proposed for development will 1) allow for a measurement of the heterogeneity of concentration of receptors in cell populations, and 2) the proportion of cells in a tumor population that have estrogen receptor above a certain concentration level. The recent development of monoclonal antibodies against estrogen receptor makes the development of methods for immunocytochemical localization of estrogen receptor feasible. Additional recent advances in quantitative imaging cytology can be combined wih this to develop a fast, efficient and more accurate assay method and to eliminate the visual subjective components of the method. This combination of these new techniques to produce a new quantitative assay is particularly important since it has already been shown that patients whose tumors contain estrogen receptors will have a higher probability of responding to hormonal therapy, and seem to have a better prognosis than patients whose tumors do not contain this receptor.

该项目的目标是开发定量雌激素受体 使用高分辨率数字图像显微镜测量浓度 技术。 这些技术将使受体的直接测量成为可能 浓度以细胞为基础。 这是对 目前的生化测定仅给出受体的平均值 专注。 建议开发的定量分析将 1) 允许测量受体浓度的异质性 细胞群中的细胞比例，以及 2) 肿瘤群中细胞的比例 雌激素受体高于一定浓度水平的。 这 最近开发的抗雌激素受体单克隆抗体使得 雌激素免疫细胞化学定位方法的发展 受体可行。 定量成像的其他最新进展 细胞学可以与此相结合，开发出一种快速、高效、更 准确的测定方法并消除视觉主观成分 的方法。 这些新技术的结合产生了一种新的 定量分析尤为重要，因为它已经被 研究表明，肿瘤含有雌激素受体的患者会出现 对激素治疗产生反应的可能性更高，并且似乎有 比肿瘤不含这种受体的患者预后更好。